Ainos, Inc. Overview
Pro stress-test →Ainos, Inc. is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics, with its smelltech platform powered by AI Nose and smell language model (SLM) that digitizes scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, with active clinical programs including HIV-related oral warts, primary Sjögren's syndrome, and feline chronic gingivostomatitis.
Strategic Profile
Pro stress-test →The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries, as well as senior care and women's health sectors. Ainos operates as a micro-cap public company with emerging technology in artificial olfaction and biotech therapeutics, though it remains pre-profitability with significant execution risk.
Competitive Landscape
Pro stress-test →Ainos competes in nascent smelltech/electronic olfaction space with limited direct competitors, though it faces indirect competition from traditional point-of-care diagnostics providers and from broader AI/robotics sensing companies. In immune therapeutics, VELDONA competes against conventional interferon therapies and emerging immunomodulatory biologics. The company's differentiation rests on novel AI-driven scent digitization technology and low-dose formulation approach, but remains largely unproven at scale.
Industry Context
Ainos, Inc. operates in AI-driven electronic olfaction (smelltech) and point-of-care diagnostics.
Key facts
Founded: 1984 (as Amarillo Biosciences); rebranded 2021 · Headquarters: Houston, Texas, US · Employees: 41 · Revenue: Not disclosed (449% YoY growth FY2026) · Market cap: $14-16M